Thromboprophylaxis in Abdominopelvic Oncosurgery, Single Center Experience

Sunil Subhash Joshi; Ann Grace

doi:10.51131/IJPCCR/v4i1.23.5

Article

VIEWS 3050
PDF 892

International Journal of Preclinical and Clinical Research

DOI: 10.51131/IJPCCR/v4i1.23.5

Year: 2023, Volume: 4, Issue: 1, Pages: 1-5

Original Article

Thromboprophylaxis in Abdominopelvic Oncosurgery, Single Center Experience

Sunil Subhash Joshi^{✉ 1} , Ann Grace ^2,3

¹Professor of Surgery, Chikka Ballapura Institute of Medical Sciences, Chikka Ballapura, Karnataka, 562101, India

² St Johns Medical College, Bangalore, Karnataka, India

³ Consultant General Surgeon, Jyothi Hospital Belthangady. Mangalore, Mangalore, Karnataka, India

Corresponding author ✉: [email protected]

Received Date:03 March 2023, Accepted Date:11 March 2023, Published Date:25 March 2023

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Venous thromboembolism is a serious and common condition in especially those undergoing major oncosurgery. Appropriate thromboprophylaxis results in significant reduction in morbidity and mortality associated with it. The objective of this study was to assess patterns of thromboprophylaxis in this subset and prospective development of VTE in these patients at a tertiary medical center. After ethical clearance, 100 eligible patients undergoing abdominopelvic oncosurgery at St John’s Medical College Bangalore were prospectively studied for thromboprophylaxis and Doppler screening of lower extremity DVT at 2-3 weeks post procedure. Data was analyzed using SPSS 20.0. Majority of the patients (73%) received appropriate thromboprophylaxis and all of them received some prophylaxis using heparins. Postoperative asymptomatic DVT was seen in 4% of patients. Higher age, gastrointestinal tumors, duration of anesthesia and palliative procedures indicating advanced stage strongly correlated with incidence of DVT. VTE is a significant problem associated with abdominopelvic oncosurgery and thromboprophylaxis is effective in reducing morbidity and mortality associated with it. Extended prophylaxis should be considered in patients having advanced disease.

Keywords: Deep vein thrombosis, Anticoagulation, Thromboprophylaxis, Oncosurgery

References

Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thrombosis Research. 2018;164(Suppl 1):S112–S118. Available from: https://doi.org/10.1016/j.thromres.2018.01.028
Ageno W, Grimwood R, Limbiati S, Dentali F, Steidl L, Wells PS. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 2005;90(2):220–224. Available from: https://pubmed.ncbi.nlm.nih.gov/15710575/
Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117(1):57–65. Available from: https://doi.org/10.1160/th15-08-0686
Khorana AA. Venous thromboembolism and prognosis in cancer. Thrombosis Research. 2010;125(6):490–493. Available from: https://doi.org/10.1016%2Fj.thromres.2009.12.023
Turpie AGG, Chin BSP, Lip GYH. ABC of antithrombotic therapy: Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887–890. Available from: https://doi.org/10.1136%2Fbmj.325.7369.887
Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Annals of Oncology. 2005;16(5):696–701. Available from: https://doi.org/10.1093/annonc/mdi165
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thrombosis and Haemostasis. 2017;117(02):219–230. Available from: https://doi.org/10.1160/th16-08-0615
Wells PS, Anderson DR, Ginsberg J. Assessment of Deep Vein Thrombosis or Pulmonary Embolism by the Combined Use of Clinical Model and Noninvasive Diagnostic Tests. Seminars in Thrombosis and Hemostasis. 2000;26(06):643–656. Available from: https://doi.org/10.1055/s-2000-13219
Laryea J, Champagne B. Venous thromboembolism prophylaxis. Clin Colon Rectal Surg. 2013;26(3):153–159. Available from: https://doi.org/10.1055%2Fs-0033-1351130
Key NS, Khorana AA, Kuderer NM, Bohlke K, AYYL, JIA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice. 2019;15(12):661–664. Available from: https://doi.org/10.1200/jco.19.01461
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic Therapy for VTE Disease. Chest. 2012;141(2):e419S–e496S. Available from: https://doi.org/10.1016/j.chest.2021.07.055
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. Available from: https://doi.org/10.1002/cncr.23062
Kuderer NM, Ortel TL, Francis CW. Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival. Journal of Clinical Oncology. 2009;27(29):4902–4911. Available from: https://doi.org/10.1200%2FJCO.2009.22.4584
Kalka C, Spirk D, Siebenrock KA, Metzger U, Tuor P, Sterzing D, et al. Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL) Thromb Haemost. 2009;102(1):56–61. Available from: https://doi.org/10.1160/th09-02-0097
Martino RRD, Goodney PP, Spangler EL, Wallaert JB, Corriere MA, Rzucidlo EM, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. Journal of Vascular Surgery. 2012;55(4):1035–1040.e4. Available from: https://doi.org/10.1016/j.jvs.2011.10.129
Shrikhande SV, Verma M. A Prospective Observational Study to Determine Rate of Thromboprophylaxis in Oncology Patients Undergoing Abdominal or Pelvic Surgery. Indian Journal of Surgical Oncology. 2021;12(2):279–285. Available from: https://doi.org/10.1007/s13193-021-01281-0
Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treatment Reviews. 2002;28(3):141–144. Available from: https://doi.org/10.1016/s0305-7372(02)00043-9

Copyright

© 2023 Joshi & Grace. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Published By Basaveshwara Medical College & Hospital, Chitradurga, Karnataka